"Carmustine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
| Descriptor ID |
D002330
|
| MeSH Number(s) |
D02.654.692.247 D02.948.594.247
|
| Concept/Terms |
Carmustine- Carmustine
- BCNU
- N,N'-Bis(2-Chloroethyl)-N-Nitrosourea
- 1,3-Bis(2-Chloroethyl)-1-Nitrosourea
- FIVB
|
Below are MeSH descriptors whose meaning is more general than "Carmustine".
Below are MeSH descriptors whose meaning is more specific than "Carmustine".
This graph shows the total number of publications written about "Carmustine" by people in this website by year, and whether "Carmustine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 |
| 1996 | 1 | 3 | 4 |
| 1997 | 4 | 2 | 6 |
| 1998 | 1 | 4 | 5 |
| 1999 | 3 | 6 | 9 |
| 2000 | 1 | 1 | 2 |
| 2001 | 2 | 2 | 4 |
| 2002 | 1 | 3 | 4 |
| 2003 | 2 | 3 | 5 |
| 2004 | 3 | 3 | 6 |
| 2005 | 2 | 5 | 7 |
| 2006 | 0 | 4 | 4 |
| 2007 | 0 | 2 | 2 |
| 2008 | 2 | 2 | 4 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2017 | 0 | 2 | 2 |
| 2018 | 1 | 2 | 3 |
| 2019 | 0 | 2 | 2 |
| 2020 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carmustine" by people in Profiles.
-
Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma. Bone Marrow Transplant. 2022 04; 57(4):579-585.
-
Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. Cancer. 2020 05 15; 126(10):2279-2287.
-
Outcomes of autologous stem cell transplantation in Waldenstr?m's macroglobulinemia. Ann Hematol. 2019 Sep; 98(9):2233-2235.
-
Allogeneic Transplantation after Myeloablative Rituximab/BEAM ? Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results. Biol Blood Marrow Transplant. 2019 07; 25(7):1347-1354.
-
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2018 08; 24(8):1602-1609.
-
Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma. Clin Cancer Res. 2018 05 15; 24(10):2304-2311.
-
NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients. J Neurooncol. 2018 Mar; 137(1):39-47.
-
Pretransplant functional imaging and outcome in pediatric patients with relapsed/refractory Hodgkin lymphoma undergoing autologous transplantation. Pediatr Blood Cancer. 2018 Jan; 65(1).
-
A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results. Br J Haematol. 2017 08; 178(4):561-570.
-
Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. Biol Blood Marrow Transplant. 2016 07; 22(7):1197-1205.